PRAXIS PRECISION MEDICINES, INC. (PRAX) Current Ratio
- Current ratio · latest quarter: Value 15.73×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 15.73× | Current assets / current liabilities. $771.90M ÷ $49.06M ≈ 15.73× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 771.90M USD | Assets, Current |
| Current obligations | 49.06M USD | Liabilities, Current |
| Cash and equivalents | 474.76M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 283.79M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 23.39M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $771.90M | $49.06M | $474.76M | $283.79M | (m) | (m) | $23.39M | (m) | 15.73× |
| 2026-03-31 | $797.77M | $50.24M | $536.33M | $250.53M | (m) | (m) | $31.16M | (m) | 15.88× |
| 2025-12-31 | $610.91M | $59.77M | $357.33M | $242.00M | (m) | (m) | $24.63M | (m) | 10.22× |
| 2025-09-30 | $273.84M | $52.88M | $149.53M | $117.63M | (m) | (m) | $30.82M | (m) | 5.18× |
| 2025-06-30 | $306.58M | $48.61M | $157.41M | $143.86M | (m) | (m) | $28.83M | (m) | 6.31× |
| 2025-03-31 | $333.57M | $39.52M | $165.57M | $162.42M | (m) | (m) | $22.91M | (m) | 8.44× |
| 2024-12-31 | $404.37M | $37.55M | $215.37M | $177.19M | (m) | (m) | $12.53M | (m) | 10.77× |
| 2024-09-30 | $360.05M | $32.86M | $168.65M | $188.39M | (m) | (m) | $15.01M | (m) | 10.96× |
| 2024-06-30 | $356.72M | $20.62M | $145.14M | $206.74M | (m) | (m) | $8.20M | (m) | 17.30× |
| 2024-03-31 | $211.80M | $18.79M | $151.98M | $55.44M | (m) | (m) | $9.40M | (m) | 11.27× |
| 2023-12-31 | $84.88M | $15.75M | $81.30M | $0.00 | (m) | (m) | $5.82M | (m) | 5.39× |
| 2023-09-30 | $103.33M | $16.79M | $101.08M | (m) | (m) | (m) | $7.17M | (m) | 6.15× |
| 2023-06-30 | $129.83M | $24.43M | $124.30M | (m) | (m) | (m) | $8.01M | (m) | 5.31× |
| 2023-03-31 | $94.40M | $29.92M | $80.84M | $4.98M | (m) | (m) | $16.99M | (m) | 3.16× |
| 2022-12-31 | $110.84M | $34.34M | $61.62M | $38.87M | (m) | (m) | $14.67M | (m) | 3.23× |
| 2022-09-30 | $132.31M | $28.98M | $62.44M | $61.30M | (m) | (m) | $10.12M | (m) | 4.57× |
| 2022-06-30 | $175.58M | $38.54M | $56.04M | $109.36M | (m) | (m) | $11.82M | (m) | 4.56× |
| 2022-03-31 | $234.47M | $45.22M | $77.85M | $132.73M | (m) | (m) | $13.27M | (m) | 5.18× |
| 2021-12-31 | $287.41M | $38.43M | $138.70M | $105.68M | (m) | (m) | $10.78M | (m) | 7.48× |
| 2021-09-30 | $319.34M | $24.75M | $165.68M | $112.20M | (m) | (m) | $7.54M | (m) | 12.90× |
| 2021-06-30 | $348.43M | $15.78M | $175.88M | $114.46M | (m) | (m) | $7.40M | (m) | 22.08× |
| 2021-03-31 | $278.56M | $13.74M | $131.15M | $100.57M | (m) | (m) | $5.77M | (m) | 20.28× |
| 2020-12-31 | $302.33M | $15.72M | $296.61M | (m) | (m) | (m) | $4.09M | (m) | 19.23× |
| 2020-09-30 | $115.85M | $10.38M | $114.77M | (m) | (m) | (m) | $3.45M | (m) | 11.16× |
| 2019-12-31 | $45.50M | $6.82M | $44.81M | (m) | (m) | (m) | $2.67M | (m) | 6.67× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |